Indian stocks: Visit www.stage2stocks.com →

Citius Oncology, Inc.

Stage 2 · Advancing · week 2

As of Oct 22, 2026, Citius Oncology is in Stage 2, the uptrend phase, now in week 2 (since Oct 13, 2026). It closed at $0.70, 60.0% below its 52-week high and below its 200-day average, which is falling.

Citius Oncology, Inc. focuses on the development and commercialization of targeted oncology therapies. More about the company

$0.70
-0.04% today
$74.0M · Micro cap
Market Neutral — Building

Pro read

Pro

Our read

In Stage 2, but it has already run

Setup score

—

Momentum

Steady

Edge

—

Setup-score rank among Stage 2 peers: #1 of 26 in Drug Manufacturers - Specialty & Generic · #1 of 272 in Health Care

Is CTOR early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…
Stage Cycle Timeline2023-08-16 → 2026-10-22
S2 49w
S4 18w
S4 26w
2023-08-162026-10-22
S1S2S3S4Setup score (0–10, dashed line at 5)
S? 6w → S2 49w → S3 1w → S4 18w → S1 8w → S4 12w → S1 3w → S2 11w → S3 13w → S4 26w → S1 3w → S4 8w → S1 6w → S2 1w current
Total tracked: 166 weeks across 14 stage runs.

CTOR among Drug Manufacturers - Specialty & Generic65th of 84 by relative strength

All 84 →
Stocks in Drug Manufacturers - Specialty & Generic ranked by relative strength, with stage and one-month change
#StockStageRS1M
1CPIXStage 2 · wk 2398+6.8%
2ETONStage 2 · wk 3097−10.1%
3ANIKStage 2 · wk 1596+3.5%
4IRWDStage 3 · wk 396−16.4%
5TEVAStage 2 · wk 995+3.1%
6AMRXStage 2 · wk 1995+5.9%
7KNSAStage 2 · wk 7395+6.2%
8AMLXStage 2 · wk 1593−6.6%
…65CTORStage 2 · wk 218−30.7%
vs 52W High
-60.0%
$0.49 lo$1.75 hi
60.0% below 52W high
How far this stock is from its 52-week high. A pullback of 3–20% while Stage 2 structure holds is typically a better entry than chasing near the high.
Stage Maturity
Week 2
1w13w26w
Week 2, fresh breakout
How long this stock has been in Stage 2. The sweet spot is mid-run: long enough to prove the structure holds, not so long that it's extended. Very fresh moves (weeks 1–4) often need more time to confirm.
vs 200 DMA
-17.7%
200 DMA: $0.85 · sloping down
Long-term trend anchor. When the stock and the S&P 500 are both above their 200-day averages, the backdrop supports continuation.
Rel Volume
0.43x
vs 50-day avg
Low vol (0.5–1x) on pullbacks = resting, not being sold. High vol on breakouts = commitment. Volume spike on down days is a warning sign.
Trend Health
↓
Short-term trend rolling over
Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.
1M
-30.7%
3M
+24.6%
6M
-28.4%
YTD
-35.2%
1Y
-60.9%
Scan Membership
Breakout Watch
Latest: 2025-06-26
2 appearances in last 60 days. First seen: 2023-09-26.
A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.
Recent Stage Timeline
2026-10-22S2
Wk 2 · Vol 0.43x
2026-10-21S2
Wk 2 · Vol 0.22x
2026-10-20S2
Wk 2 · Vol 1.10x
2026-10-19S2
Wk 1 · Vol 0.45x
2026-10-16S2
Wk 1 · Vol 0.13x
2026-10-15S2
Wk 1 · Vol 0.10x
2026-10-14S2
Wk 1 · Vol 0.24x
2026-10-13S21→2
Wk 1 · Vol 0.85x
2026-10-12S1
Wk 6 · Vol 0.60x
2026-10-09S1
Wk 6 · Vol 0.63x
2026-10-08S1
Wk 6 · Vol 0.51x
2026-10-07S1
Wk 6 · Vol 0.96x
Moving averages & range
50 DMA
$0.86
200 DMA
$0.85
52W High
$1.75
52W Low
$0.49
5D Low
$0.67
Resistance levels (recent highs)
20d High
$1.05
60d High
$1.14
120d High
$1.14
250d High
$1.75
Next resistance
+50.0%
to 20d High
ROE
-126.6%
Profit margin 0.0%
Dividend Yield
0.00%
P/B 1.8

Citius Oncology: quick answers

What stage is Citius Oncology in?

As of Oct 22, 2026, Citius Oncology (CTOR) is in Stage 2, the uptrend phase. It entered Stage 2 on Oct 13, 2026 and is in week 2. What the four stages mean

Is Citius Oncology in an uptrend?

Yes. Citius Oncology is in a Stage 2 uptrend. It trades 17.7% below its 200-day average, which is falling.

How far is Citius Oncology from its 52-week high?

Citius Oncology closed at $0.70 on Oct 22, 2026, 60.0% below its 52-week high of $1.75. Its 52-week low is $0.49.

How has Citius Oncology performed over the past year?

As of Oct 22, 2026, Citius Oncology is down 60.9% over the past year and down 35.2% so far in 2026.

Which sector and industry is Citius Oncology in?

Citius Oncology is in the Drug Manufacturers - Specialty & Generic industry, part of the Health Care sector.

About this companyHealth Care· Drug Manufacturers - Specialty & Generic

Citius Oncology, Inc. focuses on the development and commercialization of targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adult patients with relapsed or refractory cutaneous T-cell lymphoma, a rare form of non-Hodgkin lymphoma. The company is headquartered in Cranford, New Jersey. Citius Oncology, Inc. operates as a subsidiary of Leonard-Meron Biosciences, Inc.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.